Evaluation of Distance Metrics for Ligand‐Based Similarity Searching

Ligand-based similarity metrics are frequently and successfully employed for diversity analysis and the selection of activity-enriched subsets in early-phase virtual screening and compoundlibrary design. As they come in many varieties, it is not trivial to choose the most appropriate concept for the task at hand. Fundamentally, these methods rely on representative reference structures (also termed TMquery∫ or TMseed∫ structures), molecular descriptors that are correlated with biological activity, and an appropriate similarity metric. TMRetrospective screening∫ provides a means of evaluating these factors. The basic idea is to select a subset from a large pool of compounds (typically a compound database or a virtual library) and try to maximize the number of known actives in the subset, thereby forming a TMfocused library∫. Subset selection is based on the pairwise similarity between the query structure and each molecule in the pool. The result of this calculation is a list ranked by similarity. Such a retrospective screening experiment can be rated by the enrichment factor, ef [Eq. (1)] . 6] A method that is superior to a random selection of compounds returns an ef>1.

[1]  Pierre Acklin,et al.  Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..

[2]  Gisbert Schneider,et al.  Ligand-based combinatorial design of selective purinergic receptor (A2A) antagonists using self-organizing maps. , 2003, Journal of combinatorial chemistry.

[3]  Gerhard Klebe,et al.  Screening of Drug Databases , 2004 .

[4]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[5]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[6]  Peter Willett,et al.  Descriptor‐Based Similarity Measures for Screening Chemical Databases , 2000 .

[7]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[8]  Gisbert Schneider,et al.  „Grundgerüstwechsel”︁ (Scaffold‐Hopping) durch topologische Pharmakophorsuche: ein Beitrag zum virtuellen Screening , 1999 .

[9]  P. Widdowson,et al.  The development of overt diabetes in young Zucker Diabetic Fatty (ZDF) rats and the effects of chronic MCC‐555 treatment , 1998, British journal of pharmacology.

[10]  I. Dukes,et al.  Chapter 21 – Recent Advances in the Development of Agents for the Treatment of Type 2 Diabetes , 1998 .

[11]  Gisbert Schneider,et al.  Collection of bioactive reference compounds for focused library design , 2003 .

[12]  F. Holsboer,et al.  Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. , 1993, European journal of pharmacology.

[13]  John P. Overington,et al.  Chapter 28. Recent development in cheminformatics and chemogenomics , 2003 .

[14]  T. Willson,et al.  The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.

[15]  B. Komm,et al.  Chapter 15. Targeting the estrogen receptor with SERMs , 2001 .

[16]  R. Venkataraghavan,et al.  Atom pairs as molecular features in structure-activity studies: definition and applications , 1985, J. Chem. Inf. Comput. Sci..

[17]  Huafeng Xu,et al.  Retrospect and prospect of virtual screening in drug discovery. , 2002, Current topics in medicinal chemistry.

[18]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[19]  Petra Schneider,et al.  Comparison of correlation vector methods for ligand-based similarity searching , 2003, J. Comput. Aided Mol. Des..

[20]  A. Nadzan Chapter 13. Retinoids for the Treatment of Oncological Disease , 1995 .